Cytokinetics (NASDAQ:CYTK) CEO Robert Blum Sells 97,926 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 97,926 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $69.33, for a total transaction of $6,789,209.58. Following the completion of the transaction, the chief executive officer directly owned 385,320 shares in the company, valued at $26,714,235.60. This trade represents a 20.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Price Performance

CYTK stock opened at $69.31 on Wednesday. The business has a 50 day simple moving average of $77.46 and a 200-day simple moving average of $72.80. The firm has a market capitalization of $8.62 billion, a PE ratio of -9.60 and a beta of 0.36. Cytokinetics, Incorporated has a 1 year low of $47.22 and a 1 year high of $88.31.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.13. The company had revenue of $28.62 million for the quarter, compared to analysts’ expectations of $17.59 million. The business’s quarterly revenue was down 57.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.12) EPS. On average, equities research analysts expect that Cytokinetics, Incorporated will post -5.98 EPS for the current year.

Institutional Investors Weigh In On Cytokinetics

A number of institutional investors and hedge funds have recently made changes to their positions in CYTK. Norges Bank acquired a new position in shares of Cytokinetics in the fourth quarter worth $51,281,000. Siren L.L.C. acquired a new stake in shares of Cytokinetics in the first quarter valued at $40,466,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Cytokinetics by 151,987.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock valued at $35,949,000 after acquiring an additional 565,393 shares in the last quarter. ExodusPoint Capital Management LP purchased a new position in Cytokinetics in the fourth quarter valued at $21,803,000. Finally, BNP Paribas Financial Markets boosted its holdings in Cytokinetics by 134.3% in the fourth quarter. BNP Paribas Financial Markets now owns 579,862 shares of the biopharmaceutical company’s stock valued at $36,844,000 after purchasing an additional 332,397 shares during the period.

Wall Street Analysts Forecast Growth

CYTK has been the subject of a number of analyst reports. Mizuho upped their price objective on shares of Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, June 24th. JPMorgan Chase & Co. boosted their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. HC Wainwright reissued a “buy” rating and issued a $140.00 price target on shares of Cytokinetics in a research note on Monday, August 31st. UBS Group upgraded Cytokinetics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $69.00 to $115.00 in a report on Monday, June 29th. Finally, Truist Financial increased their price objective on Cytokinetics from $106.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Eighteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cytokinetics has an average rating of “Moderate Buy” and an average price target of $103.37.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Neutral Sentiment: CEO Robert I. Blum sold a combined 105,426 shares for approximately $7.34 million across September 14–15, reducing his direct holdings by roughly 22%. Because the sales were made under a pre-arranged Rule 10b5-1 plan, they may reflect scheduled portfolio diversification rather than a reaction to new company-specific information. SEC Form 4 filing
• Neutral Sentiment: Director Robert Landry separately sold 1,000 shares for $72,130 under a 10b5-1 plan. The relatively small transaction adds to the insider-selling activity but is not, by itself, a major fundamental signal. SEC director Form 4 filing
• Neutral Sentiment: Cytokinetics announced its ninth annual communications grant program, which will support cardiovascular-disease patient advocacy organizations. The initiative supports stakeholder engagement and awareness but is unlikely to materially affect near-term revenue or valuation. Grant program announcement
• Neutral Sentiment: Management presented at the Morgan Stanley Global Healthcare Conference, giving investors an opportunity to assess the company’s pipeline and commercialization plans. No clearly identified new major catalyst was provided in the supplied coverage. Morgan Stanley conference transcript
• Negative Sentiment: Commentary titled “Why Myqorzo Doesn’t Make Me a Buyer Yet” reflects investor caution about Myqorzo’s ability to establish a sufficiently attractive commercial opportunity. That skepticism can pressure CYTK until prescriptions, adoption, and revenue traction provide stronger evidence of the drug’s potential. Myqorzo investment commentary

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. The company applies expertise in muscle physiology and contractility to develop potential treatments for cardiovascular and neuromuscular diseases.

Its leading programs include aficamten, an investigational cardiac myosin inhibitor being developed for conditions involving abnormal heart-muscle contraction, including hypertrophic cardiomyopathy.